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A B S T R A C T
Objective. B-type natriuretic peptide (BNP) has diagnostic, prognostic, and therapeutic roles in adults with heart
failure. BNP levels in children undergoing surgical repair of congenital heart disease (CHD) were characterized
broadly, and distinguishable subgroup patterns delineated.
Design. Prospective, blinded, observational case series.
Setting. Academic, tertiary care, free-standing pediatric hospital.
Patients. Children with CHD; controls without cardiopulmonary disease.
Interventions. None.
Measurements. Preoperative cardiac medications/doses, CHD lesion types, perioperative BNP levels, intraopera-
tive variables (lengths of surgery, bypass, cross-clamp), postoperative outcomes (lengths of ventilation, hospitaliza-
tion, open chest; averages of inotropic support, central venous pressure, perfusion, urine output; death, low cardiac
output syndrome (LCOS), cardiac arrest; readmission; and discharge medications).
Results. Median BNP levels for 102 neonatal and non-neonatal controls were 27 and 7 pg/mL, respectively. Serial
BNP measures from 105 patients undergoing CHD repair demonstrated a median postoperative peak at 12 hours.
The median and interquartile postoperative 24-hour average BNP levels for neonates were 1506 (782–3784) pg/mL
vs. 286 (169–578) pg/mL for non-neonates (P < 0.001). Postoperative BNP correlated with inotropic requirement,
durations of open chest, ventilation, intensive care unit stay, and hospitalization (r = 0.33–0.65, all P < 0.001).
Compared with biventricular CHD, Fontan palliations demonstrated lower postoperative BNP (median 150 vs.
306 pg/mL, P < 0.001), a 3-fold higher incidence of LCOS (P < 0.01), and longer length of hospitalization (median
6.0 vs. 4.5 days, P = 0.01).
Conclusions. Perioperative BNP correlates to severity of illness and lengths of therapy in the CHD population,
overall. Substantial variation in BNP across time as well as within and between CHD lesions limits its practical utility
as an isolated point-of-care measure. BNP commonly peaks 6–12 hours postoperatively, but the timing and
magnitude of BNP elevation demonstrates notable age-dependency, peaking earlier and rising an order of magnitude
higher in neonates. In spite of higher clinical acuity, non-neonatal univentricular CHD paradoxically demonstrates
lower BNP levels compared with biventricular physiologies.
Key Words. Natriuretic Peptides; Congenital Heart Defects; Congestive Heart Failure; Low Cardiac Output;
Perioperative Care; Nesiritide
Introduction
As a diagnostic test, B-type natriuretic peptide(BNP) levels are sensitive and specific for the
presence and magnitude of congestive heart failure
(CHF) in adults and children, being elevated in
settings of systolic and diastolic dysfunction, both
acute and chronic.1,2 BNP is a prognostic marker
for common endpoints in adult and pediatric
CHF—including readmission rates, lengths of stay,
mortality, and other untoward outcomes.3–9 The
Institution where work was performed: Rady Chil-
dren’s Hospital, San Diego, CA, USA.
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recent availability of point-of-care BNP assays and
therapeutic BNP (nesiritide) has stimulated a great
deal of contemporary research. Several reviews
have recently been undertaken in pediatrics that
acknowledge that perturbations of the natriuretic
hormone system are common in the settings of
critical illness and congenital heart disease (CHD)
but assert that further investigation is needed
before this measure is of practical utility in these
populations.10–16
As a therapeutic agent, human recom-
binant BNP (hrBNP) has been used to treat
adults and children with decompensated CHF,
demonstrating some improvements in cardiac
performance.17–19 While garnering early enthusi-
asm, several studies subsequent to Food and
Drug Administration approval have questioned
the safety of therapeutic hrBNP, noting possible
increased risks of renal dysfunction and morta-
lity.20–22 A prospective study of hrBNP in adults is
expected to be completed in 2010 and should
inform current safety concerns.23
While extrapolations might be reasonably made
from adult CHF populations to children with ana-
tomically normal but failing hearts, less is known
about the utility of BNP in the perioperative man-
agement of children undergoing repair of CHD.
Because of the numerous congenital cardiac
defects, intracardiac shunting, complex pressure-
volume loading, as well as the marked physiologic
elevation in the neonatal period, BNP may well
have conditional validity and variable cutoffs as a
marker for cardiac function in specific types of
CHD.8,9,11,24–29
The literature regarding BNP in CHD has
largely been descriptive, demonstrating broad
correlations to severity of illness and adverse
clinical outcomes, and also suggesting possible
cutoff points for risk stratification. However, there
remains little data to suggest how measuring BNP
levels could guide perioperative decision making
or therapy in any practical sense.13,14,24,30–34 There-
fore, we sought to look at similar perioperative
CHD BNP data from a different vantage point.
Beyond further characterization of perioperative
BNP levels generally, our efforts were aimed
at identifying circumstances where BNP levels
appeared disproportionately low relative to the
clinical severity of CHF compared with other
CHD patients. Such subpopulations might theo-
retically benefit from administration of hrBNP
based on a theragnostic rationale, possibly giving




This study was approved by an institutional review
board (IRB) and was conducted at Rady Children’s
Hospital in San Diego, California. All the subjects’
legal guardians signed a written consent. Where
possible, developmentally appropriate subjects
signed a written assent.
This prospective observational study enrolled
subjects from birth through 22 years of age with
any congenital heart lesion undergoing open
surgical repair. For a normative control group, a
convenience blood sample was obtained and BNP
measured in children without cardiopulmonary
disease who were undergoing sedation or general
anesthesia for minor procedures or imaging. For a
surgical stress control group, BNP was measured
before and after prolonged, intensive surgeries
in children without cardiopulmonary disease.
Patients, surgeons, and anesthesiologists were
blinded to the measured BNP values of all the
subjects and the controls. Operative variables
were obtained, including cardiac lesion(s), surgical
correction(s), and durations of surgery, cardio-
pulmonary bypass, and aortic cross-clamp. These
subjects were comanaged postoperatively in two
separate care units—the Pediatric Intensive Care
Unit (PICU) and the Neonatal Intensive Care
Unit (NICU)—based on age. Cardiology and
cardiothoracic surgical teams were the same, but
intensivists and support staff differed in these
ICUs.
Blood samples were analyzed for BNP using
the Triage Meter (Biosite, Inc., San Diego, CA,
USA) in accordance with the product insert. In
the main study group, BNP was measured at the
following times: preoperatively, on arrival to the
intensive care unit postoperatively, every 6 hours
for 24 hours, daily through postoperative day
number 5, before and after specified events (e.g.,
extubation, extra-corporeal membrane oxygen-
ation (ECMO) initiation, chest closure, operative
revisions), and upon exiting the ICU or becom-
ing non-ICU status. Samples were no longer
obtained after the patients left the ICU, even if
this occurred before postoperative day number 5.
For comparative and statistical purposes, the fol-
lowing isolated and composite BNP measures
were established for each patient: preoperative
BNP, peak BNP postoperatively, 24-hour average
BNP postoperatively, and maximum positive
change in BNP over 6 hours during the first
postoperative day.
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Clinical data were obtained with each postop-
erative BNP sample, including urine output,
central venous pressure (CVP), clinical perfusion
assessment by nursing, and cardiovascular medica-
tions with doses. Composite scores were created
from serial data obtained on postoperative day 1.
These composite postoperative outcome measures
included daily averages of clinical perfusion, ino-
tropic support, and CVP. Perfusion was scored 0–4
points for each of three aspects routinely charted
by the bedside nurse in all cardiac patients—
capillary refill, peripheral pulses, and extremity
temperature—for a total range of 0–12. An inotro-
pic score with a potential range of 0–8 was
devised based on the number of four agents com-
monly used and on dose ranges reflective of local
titration practice patterns (0 points if inotropic
agent absent; +1 point if dopamine <5 mcg/kg/m,
epinephrine <0.05 mcg/kg/m, dobutamine
<5 mcg/kg/m, or milrinone 1 mcg/kg/m; +2
points if dopamine 5 mcg/kg/m, epinephrine
0.05 mcg/kg/m, dobutamine 5 mcg/kg/m,
milrinone >1 mcg/kg/m). All composite scores
described herein were devised strictly for analysis
in this study. Low cardiac output syndrome
(LCOS) was prospectively defined as 2 or more of
the following clinical signs or symptoms—
specifically oliguria (<0.5 mL/kg/hour), perfusion
impairment (perfusion score <5), or hemodynamic
impairment (CVP >15 mm Hg)—without consid-
eration of laboratory findings.36 Finally, open chest
status, as well as lengths of mechanical ventilation,
critical care status, and hospitalization, were
recorded.
Between November 2003 and May 2005, a total
of 221 patients were enrolled—102 normative
controls, 13 surgical stress controls, and 106 con-
genital heart lesion repairs. One of the CHD
patients was transferred to another ICU after
surgery and was unable to be followed up.
Statistical Analysis
This sample was analyzed as a group and by
subsets based on age, care unit, cardiac lesion,
surgical repair, and final cardiac physiology. Dis-
tributions and time-vs.-BNP curves were plotted
to characterize aggregate and subset samples. The
distributions of BNP values were consistently
asymmetric (medians lower than means) and
CHD-specific subsets of the sample were rela-
tively small. Therefore, nonparametric statistical
tests were generally preferred, and data were not
transformed except for graphical display. The
Mann–Whitney rank-sum test was used for two
sample comparisons and Wilcoxon’s signed-rank
test for matched pairs. Fisher’s exact test was used
for 2-by-2 nominal comparisons of groups. Spe-
cific associations between BNP measures, opera-
tive variables, and postoperative outcomes were
prospectively sought, and where additional pat-
terns emerged, these were explored on a post hoc
basis. Corrections of P values were not made for
multiple simultaneous tests, given the exploratory
nature of the post hoc analyses. For BNP assay
results outside the range of the BNP meter, the
range limit was used for statistical calculations.
Results
Normative BNP levels obtained from 102 subjects
from adjusted gestational age of 30 weeks through
22 years sorted clearly into two populations: neo-
nates and preterm infants <44 weeks adjusted ges-
tational age, and infants >4 weeks of age and older
children. The difference in medians between the
neonates plus preterm infants vs. all the older chil-
dren was 27 vs. 7 pg/mL, respectively (P < 0.001).
The BNP levels in non-neonatal children are low
and narrowly distributed (median of 6.9 pg/mL,
interquartile range of 5–13.3 pg/mL, and a
maximum of 52.1 pg/mL).
Thirteen surgical stress controls ages 0.4–17
years (median 9.4 years) underwent prolonged
invasive surgeries (the majority were anterior–
posterior spinal fusions) with a median intraopera-
tive duration of 3.8 hours (range 2.3–5.3 hours)
and volume administration of 30 mL/kg (range
12–92 mL/kg). Median preoperative and postop-
erative BNP were both 6.9 pg/mL, with maximal
changes of +1.3 and -6.6 pg/mL. Changes did not
correlate to surgical duration or administration of
volume.
Serial BNP measurements were obtained from
105 children undergoing repair of CHD. Table 1
summarizes the characteristics of this surgical
cohort. The majority of the patients were cared for
in the PICU (n = 91) and a minority in the NICU
(n = 14). Because of the striking difference in
neonatal BNP levels (not unlike the neonatal
controls), statistical analyses were segregated
by neonatal vs. non-neonatal status, except when
comparing these two groups.
Median preoperative and postoperative
BNP levels in non-neonatal CHD were 22 and
41 pg/mL (median change of +19 pg/mL, P <
0.001), and neonatal CHD repairs demonstrated
respective levels of 2370 and 2140 pg/mL (median
change of -230 pg/mL, P = 0.9). Age was plotted
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against 24-hour avg BNP in the CHD population,
irrespective of cardiac lesion (Figure 1). BNP levels
were higher in younger children, both within
and between preoperative diagnostic categories,
with a more marked and prolonged inverse age-
dependence in CHD patients than in controls.
Of the composite BNP scores devised, the post-
operative 24-hour average BNP (24-hour avg
BNP) had the highest overall correlation to post-
operative outcomes and was therefore the pre-
ferred BNP measure for further analysis (Table 2).
The weakest correlations were between postop-
erative BNP and intraoperative variables, although
length of surgery was significant where the dura-
tions of cardiopulmonary bypass and aortic cross-
clamp were not. The postoperative peak BNP and
24-hour avg BNP both correlated significantly
with all postoperative outcomes noted in Table 2,
most notably, durations of open chest, ventilation,
ICU stay, and hospitalization (r = 0.51–0.65, all
P < 0.001). Preoperative BNP correlated with
24-hour avg BNP (r = 0.64, P < 0.001), but was a
weak predictor of intraoperative and postoperative
measures (r all < 0.31, where significant).
Neonates and non non-neonates demonstrated
significantly different BNP levels at all points in the
time measured (Figure 2). The highest postopera-
tive BNP occurred during postoperative day 1 in
92% of the patients, but the distribution was gen-
erally a right-skewed curve, with the mode occur-
ring at 12 hours in 48% of the non-neonates and
at 6 hours in 62% of the neonates (difference in
time to peak P < 0.001). After postoperative day 1,
the neonates most commonly demonstrated BNP
levels lower than their preoperative levels—a
pattern opposite to the non-neonates. Peak and
24-hour avg BNP were significantly higher in the
non-neonatal CHD repairs with longer ICU and
hospital stays. For the entire sample, mean BNP
levels tended to be approximately twice the median
value, and the peak BNP on postoperative day 1 was
roughly twice the postoperative 24-hour average.
The median increase in BNP from preoperative
BNP to postoperative 24-hour avg BNP in the
non-neonatal populations was 251 pg/mL (P <
0.001). Corresponding BNP levels in the neonatal
CHD population were substantially higher
(>1000 pg/mL difference, P < 0.001). The major-
ity of BNP measurements that were in excess of
the assay’s upper limit (>5000 pg/mL) occurred in
the postoperative neonates with CHD, decreasing
sensitivity to any upward trends in this subset.
Only 1 of 92 (1%) non-neonates had a peak BNP
that was lower than the preoperative BNP (72 vs.
101 pg/mL, diagnosis of pulmonary atresia with
ventriculoseptal defect). However, 2 of 10 (20%)
neonates had a preoperative BNP greater than
their postoperative peak.
Patterns of perioperative BNP expression had
great variability between and within CHD lesions
Table 1. Descriptive Statistics of Congenital Heart Disease
Subjects
Demographics Values
Age, in years, median (range) 1.0 (0–17)
Weight, in kg, median (range) 8.4 (1.9–85)
Male : female, n (%) 64:41 (61:39)
Pediatric : neonatal intensive care
unit, n (%)
91:14 (87:13)
Lesions, n (%) 105 (100)
Ventricular septal defect (VSD) 13 (12)
Tetralogy of Fallot (TOF) 12 (11)
Hypoplastic left heart syndrome
(HLHS)
11 (11)
Atrio-ventricular canal (AVC) 10 (9.5)
Complex single ventricle (CSV) 8 (7.6)
Atrial septal defect (ASD) 8 (7.6)
Transposition of the great arteries
(TGA)
6 (5.7)
Double-outlet right ventricle (DORV) 5 (4.8)
Tetrology of Fallot, repaired (TOF-R) 5 (4.8)
Pulmonary atresia + VSD (PA-VSD) 5 (4.8)






Tricuspid atresia (TA) 3 (2.9)
Others (if fewer than 3 of a lesion
type)
14 (13)
Repairs, n (%) 105 (100)
Complete repair (CR) 58 (55)
Total-cavo-pulmonary anastomosis





Stage-1 palliation (S1P), mainly
Norwoods
7 (6.7)
Arterial switch 6 (5.7)
Right ventricular outflow tract
revision (RVOT-R)
5 (4.8)





Length of surgery, in minutes,
median (range)
248 (114–807)
Length of bypass, in minutes,
median (range)
119 (0–346)
Length of cross-clamp, in minutes,
median (range)
51 (0–164)
Length of ventilator, in days, median
(range)
1.35 (0.5–59)
Length of intensive Care, in days,
median (range)
2 (1–59)
Length of hospitalization, in days,
median (range)
5 (2–64)




Deaths, n (%) 3 (2.9)
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(Figure 3), and BNP receiver–operator character-
istic (ROC) curves were generally of weak dis-
criminatory performance in our sample. The area
under the curve (AUC) for the 24-hour avg BNP
to detect LCOS was 0.61 in aggregate, 0.77 in
neonates, and 0.56 in non-neonates.
Lesion-specific subsets were generally too
small to perform meaningful statistical analyses.
When aggregated into larger subsample cate-
gories based on stage of univentricular pallia-
tion vs. complete biventricular repairs (Figure 4),
univentricular patients demonstrated a sequential
decrease in BNP levels at each stage. Median
postoperative 24-hour avg BNP for univentri-
cular patients—Stage 1 Palliations, bidirectional
Glenn anastamoses, and fenestrated fontans—
were, respectively, 778, 415, and 150 pg/mL,
whereas the biventricular CHD repairs had a
median postoperative 24-hour avg BNP of
318 pg/mL.
A post hoc comparison was made between the
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Figure 1. Preoperative and postoperative 24-hour average B-type natriuretic peptide (BNP) levels vs. patient age in
congenital heart disease (CHD) patients. Children of younger age demonstrate higher BNP levels. Distinct from normative
controls, this age-dependence in CHD persists years into childhood, and it appears to be most pronounced in postoperative
BNP levels. When analyzed within different preoperative CHD diagnostic categories, this trend persists in 10 of 13 categories
preoperatively and 13 of 13 postoperatively.
Table 2. Significant Correlations between B-Type Natriuretic Peptide Measures and Other Clinical Measures in Non-
Neonatal Congenital Heart Disease Subjects
B-Type Natriuretic Peptide (BNP) Pre-Op (r) Postoperative 24-hour Average (r)
Non-Neonatal Population (n) All (92) All (92) Biventricular (66) Fontan (16)
Length of aortic cross-clamp — — — —
Length of cardiopulmonary bypass — — — —
Length of surgery 0.21* 0.28** 0.23* —
POD 1 urine output — — — —
POD 1 perfusion score impairment — 0.28* 0.37** —
POD 1 central venous pressure — 0.27** 0.38*** —
POD 1 inotropic support score 0.26* 0.33*** 0.46*** —
Length of chest open — 0.61*** 0.55*** —
Length of ventilation 0.22* 0.51*** 0.54*** —
Length of intensive care 0.29** 0.53*** 0.53*** 0.52*
Length of hospitalization 0.31** 0.65*** 0.52*** 0.51*
Discharge diuretic dose — 0.33*** 0.26* —
Discharge ACE inhibitor dose — 0.20* 0.32* —
*P < 0.04; **P < 0.01; ***P < 0.001.
POD, postoperative day; ACE, angiotensin-converting enzyme.
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jects (Table 3). Compared with the biventricular
repairs, the Fontans demonstrated similar demo-
graphics but numerous measures of higher clinical
acuity throughout the perioperative sequence—
including higher doses of cardiovascular medica-
tions at admission and discharge, longer surgical
time, higher inotropic requirements postopera-
tively, longer length of intensive care and hospi-
talization, and increased incidence of LCOS. The
Fontan palliations demonstrated lower periopera-
tive BNP measures than biventricular repairs—
including preoperative BNP (16 vs. 23 pg/mL, P =
0.09), peak BNP (266 vs. 592 pg/mL, P < 0.001),
maximal rate of rise (24 vs. 60 pg/mL/hour, P =
0.001), and 24-hour postoperative average (150 vs.
306 pg/mL, P < 0.001). The non-neonatal CHD
sample demonstrated a positive and significant
correlation between the postoperative 24-hour avg
BNP and numerous clinical measures of acuity
(Table 2), and while the biventricular CHD corre-
lations were generally stronger, the Fontan sub-
group demonstrated weakly negative, statistically
nonsignificant correlations to most of these same
measures.
To assess the impact of cardiopulmonary
bypass on very high BNP levels, the patients
with preoperative BNP >1000 pg/mL had two
additional intraoperative BNP samples: ~5
minutes after beginning cardiopulmonary bypass
and ~5 minutes prior to unclamping the aorta. Of
the 7 subjects with preoperative BNP levels
>1000 pg/mL (all neonates), 5 were captured for
this analysis. BNP levels uniformly dropped
to a nadir at the end of aortic cross-clamp, rising
again postoperatively to near-preoperative levels
(Figure 5). The mean difference in BNP between
preoperative (3926 pg/mL) and end of the cross-
clamp (822 pg/mL) was 3104 pg/mL (P < 0.07).
Three subjects died, including one neonate
(hypoplastic left heart syndrome [HLHS] under-
going Norwood palliation) and two non-neonates


































































































Figure 2. B-type natriuretic peptide (BNP) values across time: neonatal vs. non-neonatal congenital heart disease repairs.
Neonatal and non-neonatal BNP values were distinct, both in timing of the peak and magnitude at each time point (P values
all significant). In non-neonates, BNP levels were consistently higher in children with longer lengths of ventilation, intensive
care unit (ICU) stay, and hospitalization. Later time points partly reflect patient attrition from the ICU and should not be
misconstrued to represent typical individual curves, which generally demonstrated gradual reduction in BNP after the peak
on postoperative day 1. The highest postoperative BNP occurred on postoperative day 1 in 92% of the patients, and the
distribution was somewhat right-skewed with the mode (dark triangles) occurring at 12 hours in the pediatric ICU (48% of
patients) and at 6 hours (62% of patients) in the neonatal ICU. This difference in time to peak was significant (P < 0.001).
The two T’s on the y-axis designate the upper and lower thresholds of the BNP assay.
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dure, and a pulmonary atresia-ventricular septal
defect undergoing an attempted biventricular
repair). Within the non-neonatal cohort, the two
nonsurvivors demonstrated preoperative BNP
levels in the 83rd–88th percentile (67–88 pg/mL)
and postoperative 24-hour average BNP in the
98–99th percentile (2492–2831 pg/mL). In con-
trast, the neonatal nonsurvivor’s BNP was <50th
percentile both preoperatively and postopera-
tively. If a composite measure of “adverse out-
comes” is defined as death, cardiac arrest, or ICU
length of stay >28d, a group of 5 non-neonatal
patients were identified that demonstrated a pre-
operative BNP ROC AUC of 0.83 (BNP of
>64 pg/mL yields 80% sensitivity and 85% speci-
ficity), while the 24-hour avg BNP ROC AUC is
0.96 (24-hour avg BNP of >721 pg/mL yields
80% sensitivity and 92% specificity).
Discussion
Normative pediatric BNP levels in children are
lower and more narrowly distributed than in
adults—with the notable exception of newborns
and preterm infants who may exhibit high, widely
distributed BNP levels during their circulatory
transition.37 Our data suggest a nadir in the first
year of life, after which, a gradual rise in BNP
appears to take place. No straightforward surgical
control group exists for CHD repairs, but in an
effort to compare with some kind of relatable sur-
gical stress, we selected a small sample of noncar-
diac surgeries expected to be several hours in
duration with significant intraoperative blood loss
and volume resuscitation. These controls demon-
strated normal preoperative and postoperative
BNP levels unaffected by intraoperative variables.
In contrast, the non-neonatal CHD patients’ post-
operative BNP levels rose significantly by several
orders of magnitude. This suggests that rising
BNP levels in the CHD repairs are not likely relat-
able to nonspecific surgical stresses, anesthetic
exposure, or routine intraoperative volume man-
agement for blood loss.
The vast majority of preoperative BNP levels in
non-neonatal CHD were within the commonly
accepted normative range for this assay (<100 pg/
mL), likely reflecting a state of compensated CHF.
Composite and isolated postoperative BNP levels
correlated with numerous aspects of CHF in
CHD repairs—including the timing and severity
of LCOS, duration of ICU support, discharge
medication doses, and a composite of adverse out-
comes. Because BNP usually peaked on postop-
erative day 1, and because the time to peak varied,
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Figure 3. Preoperative B-type natriuretic peptide (BNP) and postoperative 24-hour average BNP in selected congenital
heart disease lesions. Significant interindividual, interlesional, and age-dependent variability exists in BNP expression. TGA,
transposition of the great arteries; HLHS1/2, hypoplastic left heart syndrome, Stage 1/2; PA, pulmonary atresia; CSV,
complex single ventricle; DORV, double outlet right ventricle; TOF(-R), tetrology of Fallot (repaired); VSD, ventricular septal
defect; AVC, atrio-ventricular canal; ASD, atrial septal defect; MISC, miscellaneous lesions (for which n < 5 for that lesion
type). The two T’s on the y-axis designate the upper and lower thresholds of the BNP assay.
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estimate an AUC resulted in the composite
measure that best correlated to clinical measures—
and was the measure felt to be most reflective
of overall physiologic BNP response. BNP levels
appeared to behave as one might expect to
common perioperative maneuvers—rising tran-
siently after sternal closure and after discontinuing
positive pressure ventilation (data not shown)—
and generally trended down after a peak on post-
operative day 1 as the patients convalesced.
When assessed in aggregate or by CHD lesion,
BNP levels fell logarithmically with age, both pre-
operatively and postoperatively (Figure 1)—in
contrast to the normative controls that trended
upward after the neonatal period. In contrast to
neonatal controls, this inverse age-dependence of
BNP levels in CHD persisted years into life—not
merely during the period of transitional circula-
tion. While BNP trends might be influenced by
different cardiac lesions being repaired at different
ages, when analyzed within a dozen different pre-
operative diagnostic categories, this BNP-vs.-age
relationship persisted universally in postoperative
BNP and was re-demonstrated with preoperative
BNP in the vast majority of categories.
Others have reported point-in-time cutoff
values for BNP as a risk stratifier or predictor of
outcomes in CHD, and similar analyses of our
data are consistent with many of these find-
ings.7–9,14,27–29,33,34 Therefore, we looked at our
perioperative BNP data from a slightly different
perspective—seeking situations where BNP levels
and severity of illness appeared discordant. Two
such populations stood out: Fontans in general
and neonates intraoperatively.
In a small sample of non-neonatal CHD
repairs, Ationu found that preoperative BNP was
within normal limits and only trivially reduced
intraoperatively at various stages during CPB38—
much as our CHD and surgical control data show.
However, since BNP is rapidly liberated and has a
half-life of approximately 22 minutes, intraopera-
tive reductions may not be apparent in patients
with normal preoperative BNP concentrations.
Therefore, we selected CHD subjects with
preoperative BNP greater than 1000 pg/mL for
additional intraoperative BNP sampling (only
neonates had preoperative levels this high). While
a small sample, all five cases demonstrated the
same pattern: BNP levels dropped dramatically
while on cardiopulmonary bypass and reached a
nadir at the end of aortic cross-clamp. Possible
mechanisms include dilution from the proportion-
ally larger bypass circuit prime in neonates,
exclusion of the ramped up BNP-producing
myocardium from the circulating blood volume,
increased elimination efficiency by ultrafiltration,
or upregulated peripheral metabolism of BNP.
These remarkably high levels of BNP preopera-
tively may be physiologic and adaptive in neonatal
CHD, and iatrogenic reductions intraoperatively
could theoretically contribute to impaired physi-
ologic homeostasis postoperatively.
In our comparison of biventricular repairs and
Fontan palliations (Tables 2 and 3), the univen-
tricular patients demonstrated higher clinical
acuity yet significantly lower BNP measures—less
than half the average amount of BNP on postop-
erative day 1. The Fontan patients required more
cardiac medication, had longer lengths of stay,
were readmitted more often, and showed an
almost 3-fold increase in LCOS (in spite of similar
CBP run lengths). In stark contrast to biventricu-
lar CHD, the Fontan palliations paradoxically























































Figure 4. Preoperative and 24-hour average postoperative
B-type natriuretic peptide (BNP) levels in staged univen-
tricular palliations vs. complete biventricular repairs. Early
postoperative BNP expression is higher in all groups of
congenital heart disease repairs shown. In univentricular
repairs, BNP trends downward with advancing stage and
age. Pre, preoperative; Post, postoperative; Norwood, pre-
dominantly Norwoods plus similar stage-1 palliations;
Glenn, predominantly bidirectional Glenns plus similar
superior cavopulmonary anastamoses; Fontan, fenestrated
Fontans; Bi-Vent, complete biventricular repairs. The two
T’s on the y-axis designate the upper and lower thresholds
of the BNP assay.
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BNP and both CVP as well as inotrope score.
With only 6 bidirectional Glenn anastamoses,
analyses of this univentricular stage were quite
limited statistically, but in general, these patients
demonstrated similar BNP measures but worse
clinical outcomes than the biventricular repairs—
also suggesting a degree of discord between BNP
and outcomes in this univentricular population.
These findings supplement previous reports by
others citing progressively lower BNP expression
in staged univentricular CHD repairs—perhaps
because of isolated cavopulmonary failure or
impaired perioperative expression of natriuretic
peptides.24,26,28 These data also give us cause to
consider whether BNP levels are mal-aligned with
the clinical severity of CHF in these populations.
While speculative, impairment of an otherwise
adaptive BNP response in this population could
conceivably contribute to the tendency of univen-
tricular patients to require greater medical support
and exhibit longer lengths of stay.
Measured BNP levels clearly reflect an equilib-
rium between many variables: production, degra-
dation, endocytosis, excretion, and dilution. This
can seriously confound the interpretation of BNP
in perioperative CHD when many of these
variables are not in a predictable steady state. Yet,
with the exception of overt renal dysfunction,
measured BNP levels appear to predominantly
reflect production by the ventricular myocar-
dium.39,40 However, while BNP correlates to clini-
cal measures and predicts poor outcomes (similar
to many biomarkers), it does not reveal much
that is not already apparent to clinicians—that
sicker patients require more support for a longer
time and tend to do worse. Indeed, the existing
literature on BNP in perioperative CHD does not
meaningfully guide therapy, and BNP risk strati-
fication has not translated into differing manage-
ment algorithms.14,37,38,41–45
Questions clearly remain regarding the app-
ropriateness and effectiveness of endogenous
Table 3. Comparison of Perioperative Measures between Fontan Palliations and Non-Neonatal Complete Biventricular
Congenital Heart Disease Repairs
Type of Surgical Repair/Palliation Complete (Biventricular) Fontan (Univentricular) P
Demographics
Sample Size (n) 66 16
Age (in years, median/IQR) 1.2 (0.4–4.2) 1.7 (1.5–2.8) —
Weight (in kg, median/IQR) 9.0 (5.5–16) 10.5 (9.5–12.4) —
Admission measures (median/IQR)
Number of cardiovascular medications 0.5 (0–2) 1 (1–2) —
Furosemide/equivalent dose (mg/kg/d) 0 (0–1.2) 0.3 (0–1.2) —
Captopril/equivalent dose (mg/kg/d) 0 (0–0) 0.3 (0.05–0.6) <0.001
BNP measures (median/IQR)
BNP, preoperative (pg/mL) 23 (12–53) 16 (9–30) 0.09
BNP, peak postoperative (pg/mL) 592 (432–1150) 266 (178–442) <0.001
BNP, 24-h postoperative average (pg/mL) 306 (226–604) 150 (102–244) <0.001
BNP, maximum rate of increase (pg/mL/h) 60 (31–108) 24 (19–49) 0.001
Intraoperative measures (median/IQR)
Length of aortic cross-clamp (min) 56 (42–87) 52 (39–59) —
Length of cardiopulmonary bypass (min) 119 (88–160) 119 (105–139) —
Length of surgery (hours) 3.8 (2.9–4.7) 4.8 (4.2–5.8) 0.001
Clinical post-op measures (median/IQR)
POD 1 central venous pressure (mm Hg)* 9.8 (7.8–13.2) 13.5 (11.5–15.3) <0.001
POD 1 perfusion score impairment (0–12) 1.6 (1.1–2.2) 2.2 (1.2–2.9) —
POD 1 inotropic support score (0–8) 2 (1.2–2.4) 2.4 (1.8–2.8) 0.04
POD 1 urine output (mL/kg/hr) 2.3 (1.7–3.2) 1.9 (1.5–2.7) —
Duration post-op measures (median/IQR)
Length of ventilation (days) 1.3 (0.8–2.6) 1.1 (0.9–1.5) —
Length of intensive care (days) 2.0 (1–4) 3.0 (2–3.5) 0.08
Length of hospitalization (days) 4.5 (3–7) 6.0 (5.5–7.5) 0.01
Discharge measures (median/IQR)
Number of cardiovascular medications 2 (1–3) 3 (3–3) 0.001
Furosemide/equivalent dose (mg/kg/day) 2.6 (1.3–3.0) 2.9 (2.6–3.1) 0.09
Captopril/equivalent dose (mg/kg/day) 0 (0–0.5) 0.7 (0.5–1) <0.001
Binary outcomes
Low cardiac output syndrome (n, %) 13 (20) 9 (56) <0.01
Open chest postoperatively (n, %) 4 (6.1) 0 (0) —
Deaths (n, %) 1 (1.5) 0 (0) —
Readmission <6 weeks from discharge (n, %) 2 (3.0) 2 (12) —
*Represents pulmonary artery pressure for Fontan physiology.
BNP, B-type natriuretic peptide; IQR, interquartile range; POD, postoperative day.
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BNP levels after CHD repair. In contrast to car-
diomyopathies, CHD can have unique ventricular
pressure-volume loading states because of parallel
circulation, intracardiac shunting, single ventricle
physiologies, ventricular reversals, and complex
surgical reconfigurations. Univentricular CHD
may have relatively less BNP-producing myocar-
dium. Certainly, the myocardium is not able to
effectively liberate BNP during asystole following
cardioplegia. It may be that such aspects of CHD
could alter the normal adaptive function of this
important counter-regulatory signal, resulting in
BNP responses that are inappropriately low or
high relative to the clinical magnitude of heart
failure.
The off-label use of hrBNP in children under-
going CHD repair has been undertaken—with
retrospective analyses and case series suggesting
improved surrogate endpoints and an absence of
obvious complications.19,23,46–49 However, clear
indications, proven efficacy, and convincing safety
have not been demonstrated. Exogenous BNP has
several theoretically desirable features in the
care of postoperative CHD patients, including
vasodilitation, diuresis, and lusitropy. Yet, meta-
analyses of adult trials with hrBNP have raised
concerns about increased renal dysfunction and
mortality—so any therapeutic manipulations of
the BNP axis ought not be applied indiscrimi-
nately without further guiding evidence.21,22 The
prospect of perioperative BNP elevations insuffi-
cient for optimal adaptation would provide a
tempting mechanistic rationale for considering
exogenous BNP in targeted CHD populations.
Because nesiritide is a recombinant form of a
human protein naturally found highly concen-
trated in children with heart failure, the drug may
prove to be a safe and effective therapy in situa-
tions of relative deficiency—in contrast to creating
supraphysiologic levels beyond the expected adap-
tive response in cardiomyopathy.
While our data do not definitively identify
states of relative BNP insufficiency, it will remain
challenging to tease out such a condition given the
enormous variability in BNP responses superim-
posed on the clinical complexity of perioperative
CHD. In this confounded and heterogeneous
clinical setting, a theragnostic approach may be
productive—using a biomarker to identify which
patients are most likely to benefit from a specific
drug therapy.35 Therefore, we suggest that a ratio-
nale exists for further research into targeted
administration of hrBNP in some circumstances
encountered in the perioperative management
of CHD. These include: patients undergoing
cardiopulmonary bypass with very high BNP
levels preoperatively (in an effort to replace any
iatrogenic decrement in an adaptive hormone)
and postoperatively to univentricular palliations
(where our data show relatively low BNP levels
compared with clinical acuity). Clinical trials
assessing the safety and efficacy of hrBNP in such
circumstances should be undertaken, and our
data provides a starting point for mechanistically
guided use in future research.
There are significant limitations to our data
limiting generalizability. The heterogeneous
sample unevenly distributed among numerous
small CHD subsets makes our aggregate analyses
difficult to extrapolate to individual CHD lesions.
In particular, the NICU subjects were only
enrolled in the last third of the study window
after an IRB amendment, resulting in a particu-
larly small neonatal subsample. There was also a
paucity of hemi-Fontans, further limiting the
kinds of univentricular subgroup analyses that
could be made. As a matter of feasibility and con-
venience in this unfunded study, a perfusion score
was devised based on routine nursing assessments,


















>5000 pg/mL above threshold of assay
Figure 5. Intraoperative B-type natriuretic peptide (BNP)
levels in five congenital heart disease repairs exhibiting
markedly high preoperative BNP levels. In patients with
very high levels of BNP preoperatively (all neonates), car-
diopulmonary bypass and circulatory arrest consistently
lowered serum BNP concentrations by thousands of pg/mL,
which rose quickly postoperatively to near-preoperative
levels. Pre-Op, preoperative; On CBP, ~5 minutes into car-
diopulmonary bypass; End XC, ~5 minutes prior to unclamp-
ing aorta; Post-Op, upon arrival to the intensive care unit
(ICU) postoperatively (hour 0 of BNP series in ICU).
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ture differentials. Also, an inotropic score was
devised that weighted low, moderate, and high
dosing levels in a manner that was felt to reflect
local titration patterns. Because it used collapsed
dose ranges rather than linear conversions, it is
presumably less sensitive than other tools. While
neither of these scales devised for this study are
validated measures, they did both correlate as
expected with other objective measures of clinical
acuity and with each other. Apart from urine
output, renal function was not measured, but since
impaired renal function can result in elevated BNP
levels, this is a potential confounder. However,
BNP and UO did not correlate positively or nega-
tively on postoperative day 1. Another limitation is
the management of CHD by two different ICUs
and intensivists groups within our institution,
potentially introducing systematic differences in
the assessment and management. However, the
cardiothoracic surgeons and cardiologists were the
same, and the strikingly higher levels of BNP in
the neonatal population (controls and CHD) sug-
gests that this group needs to be analyzed sepa-
rately from older infants and children regardless.
Because perioperative BNP levels in the NICU
population were frequently above the upper limit
of measurability, the upper range limit of the
meter was used in calculations, likely blunting the
sensitivity of this measure in our analyses. Future
research including neonates should consider more
accurate methods of measuring very high BNP,
such as through dilutional techniques or alterna-
tive assays. Finally, corrections of P values were
not made for multiple simultaneous tests, given
the exploratory nature of the post hoc analyses, so
marginally significant values should be treated
with caution.
Conclusions
BNP is a valid biomarker for CHF in the CHD
population during the perioperative period.
Levels correlate to clinical severity of heart
failure, lengths of therapy, and adverse outcomes.
Peak BNP levels most often occurred 6–12 hours
postoperatively, mirroring the classic period of
the LCOS. However, the clinical utility of BNP
as a rapid point-of-care diagnostic assay is limited
after CHD repair because of the highly variable
responses between and within CHD lesions
as well as age-dependency. Randomly obtained
BNP levels will remain difficult to interpret
without other points on the BNP-vs.-time curve
of an individual patient. Despite having greater
clinical acuity and resource utilization, Fontan
palliations paradoxically exhibited lower BNP
expression preoperatively and postoperatively
compared with biventricular CHD. This pattern
of potential BNP insufficiency, as well as others
described here, suggest rational targets for inves-
tigating therapeutic administration of hrBNP
perioperatively.
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